<DOC>
	<DOCNO>NCT01944228</DOCNO>
	<brief_summary>The purpose study assess effect transvenous vagus nerve stimulation ( tVNS ) immune response . In human endotoxemia model , intravenously administer endotoxin ( lipopolysaccharide [ LPS ] ) elicit systemic immune response release pro-inflammatory cytokine , TNF α . This trial determine anti-inflammatory effect produce acute VNS use minimally invasive delivery method .</brief_summary>
	<brief_title>Effects Transvenous Vagus Nerve Stimulation Immune Response : Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<criteria>1 . Written inform consent participate trial 2 . Male subject age 18 35 year inclusive 3 . Healthy determine medical history , physical examination , vital sign , 12 lead electrocardiogram , clinical laboratory parameter Use medication ( include herbal remedy vitamin/mineral supplement ) recreational drug within 7 day prior profile day Smoking Use caffeine , alcohol within 1 day prior profile day Previous participation trial LPS administer Surgery trauma significant blood loss blood donation within 3 month prior profile day Participation another clinical trial within 3 month prior profiling day . History , sign symptoms cardiovascular disease An implant opinion investigator may make invasive procedure risky subject due increase risk associate possible infection . Subject implant active cardiac device ( ICD , IPG and/or CRT ) Implanted active neurostimulation device Subject internal jugular vein access History vasovagal collapse orthostatic hypotension History atrial ventricular arrhythmia Resting pulse rate ≤45 ≥100 beat / min Hypertension ( RR systolic &gt; 160 RR diastolic &gt; 90 ) Hypotension ( RR systolic &lt; 100 RR diastolic &lt; 50 ) Conduction abnormality ECG consist 1st degree atrioventricular block complex bundle branch block Subject diagnose epilepsy history seizure Renal impairment : plasma creatinine &gt; 120 µmol/L Liver function abnormality : alkaline phosphatase &gt; 230 U/L and/or ALT &gt; 90 U/L Coagulation abnormality : APTT PT &gt; 1.5 time reference range History asthma Immunodeficiency CRP &gt; 20 mg/L , WBC &gt; 12x109/L , clinically significant acute illness , include infection , within 2 week profile day Known suspect able comply trial protocol Inability personally provide write informed consent ( e.g . linguistic mental reason ) and/or take part study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>inflammation</keyword>
	<keyword>vagus nerve stimulation</keyword>
	<keyword>chronic heart failure</keyword>
	<keyword>Systemic Inflammatory Response Syndrome</keyword>
	<keyword>sepsis</keyword>
	<keyword>auto-immune disease</keyword>
</DOC>